An economic evaluation of vaccination in children against meningococcal infection in Moscow

Meningococcal infection (MI) is one of the most serious and life-threatening with an average mortality rate of 15 %. Infection accounts for the largest number of deaths of all infectious diseases among children under 17 years of age. Aim. Using simulation mathematical modeling to evaluate the potent...

Full description

Bibliographic Details
Main Authors: S. V. Svetlichnaya, L. N. Mazankova, L. D. Popovich, L. A. Elagina
Format: Article
Language:Russian
Published: Izdatelstvo OKI 2023-10-01
Series:Качественная клиническая практика
Subjects:
Online Access:https://www.clinvest.ru/jour/article/view/670
_version_ 1797262016357859328
author S. V. Svetlichnaya
L. N. Mazankova
L. D. Popovich
L. A. Elagina
author_facet S. V. Svetlichnaya
L. N. Mazankova
L. D. Popovich
L. A. Elagina
author_sort S. V. Svetlichnaya
collection DOAJ
description Meningococcal infection (MI) is one of the most serious and life-threatening with an average mortality rate of 15 %. Infection accounts for the largest number of deaths of all infectious diseases among children under 17 years of age. Aim. Using simulation mathematical modeling to evaluate the potential epidemiological and economic benefits of vaccination against MI for children under the age of 1 year in Moscow with a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine. Methods. The assessment of potential indicators of morbidity and mortality of children under the age of 1 year after vaccination in a hypothetic cohort was carried out, considering a period of the stable post-vaccination immunity. Data were compared with the indicators of the MI incidence in Moscow. Monetary equivalents of economic benefits are calculated, considering the cost of vaccination, direct and indirect costs. Results. It is possible to reduce the number of MI cases by 73 %, mortality by an average on 85 % after vaccination, in the horizon of 5 years of maintaining immunity tension, Vaccination of children under one year old can reduce the number of disability cases that occur after severe forms of infection. As a result, the economic impact from the mentioned disease can be reduced by 75 %. Conclusion. The resulting economic benefits in the future may significantly exceed the cost of vaccination. It seems expedient to accelerate the introduction of vaccination of children's contingents against MI.
first_indexed 2024-04-24T23:50:24Z
format Article
id doaj.art-00008316737441dd9b93a642f78397ef
institution Directory Open Access Journal
issn 2588-0519
2618-8473
language Russian
last_indexed 2024-04-24T23:50:24Z
publishDate 2023-10-01
publisher Izdatelstvo OKI
record_format Article
series Качественная клиническая практика
spelling doaj.art-00008316737441dd9b93a642f78397ef2024-03-14T18:09:10ZrusIzdatelstvo OKIКачественная клиническая практика2588-05192618-84732023-10-010341410.37489/2588-0519-2023-3-4-14633An economic evaluation of vaccination in children against meningococcal infection in MoscowS. V. Svetlichnaya0L. N. Mazankova1L. D. Popovich2L. A. Elagina3ООО «Независимый Институт социальных инноваций» (НИСИ)ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииФГАОУ ВО «Национальный исследовательский университет «Высшая школа экономики»ООО «Независимый Институт социальных инноваций» (НИСИ)Meningococcal infection (MI) is one of the most serious and life-threatening with an average mortality rate of 15 %. Infection accounts for the largest number of deaths of all infectious diseases among children under 17 years of age. Aim. Using simulation mathematical modeling to evaluate the potential epidemiological and economic benefits of vaccination against MI for children under the age of 1 year in Moscow with a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine. Methods. The assessment of potential indicators of morbidity and mortality of children under the age of 1 year after vaccination in a hypothetic cohort was carried out, considering a period of the stable post-vaccination immunity. Data were compared with the indicators of the MI incidence in Moscow. Monetary equivalents of economic benefits are calculated, considering the cost of vaccination, direct and indirect costs. Results. It is possible to reduce the number of MI cases by 73 %, mortality by an average on 85 % after vaccination, in the horizon of 5 years of maintaining immunity tension, Vaccination of children under one year old can reduce the number of disability cases that occur after severe forms of infection. As a result, the economic impact from the mentioned disease can be reduced by 75 %. Conclusion. The resulting economic benefits in the future may significantly exceed the cost of vaccination. It seems expedient to accelerate the introduction of vaccination of children's contingents against MI.https://www.clinvest.ru/jour/article/view/670менингококковая инфекциявакцинацияоценка технологии здравоохранения
spellingShingle S. V. Svetlichnaya
L. N. Mazankova
L. D. Popovich
L. A. Elagina
An economic evaluation of vaccination in children against meningococcal infection in Moscow
Качественная клиническая практика
менингококковая инфекция
вакцинация
оценка технологии здравоохранения
title An economic evaluation of vaccination in children against meningococcal infection in Moscow
title_full An economic evaluation of vaccination in children against meningococcal infection in Moscow
title_fullStr An economic evaluation of vaccination in children against meningococcal infection in Moscow
title_full_unstemmed An economic evaluation of vaccination in children against meningococcal infection in Moscow
title_short An economic evaluation of vaccination in children against meningococcal infection in Moscow
title_sort economic evaluation of vaccination in children against meningococcal infection in moscow
topic менингококковая инфекция
вакцинация
оценка технологии здравоохранения
url https://www.clinvest.ru/jour/article/view/670
work_keys_str_mv AT svsvetlichnaya aneconomicevaluationofvaccinationinchildrenagainstmeningococcalinfectioninmoscow
AT lnmazankova aneconomicevaluationofvaccinationinchildrenagainstmeningococcalinfectioninmoscow
AT ldpopovich aneconomicevaluationofvaccinationinchildrenagainstmeningococcalinfectioninmoscow
AT laelagina aneconomicevaluationofvaccinationinchildrenagainstmeningococcalinfectioninmoscow
AT svsvetlichnaya economicevaluationofvaccinationinchildrenagainstmeningococcalinfectioninmoscow
AT lnmazankova economicevaluationofvaccinationinchildrenagainstmeningococcalinfectioninmoscow
AT ldpopovich economicevaluationofvaccinationinchildrenagainstmeningococcalinfectioninmoscow
AT laelagina economicevaluationofvaccinationinchildrenagainstmeningococcalinfectioninmoscow